The FDA declined to approve one of biotech’s most closely watched cancer drugs. The company’s stock tumbled.

Source: MarketWatch ·

The FDA declined to approve one of biotech’s most closely watched cancer drugs. The company’s stock tumbled.

The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.

Read the full story at MarketWatch

Shared from the GodsView world desk: live wires next to a globe of flights, ships, fires, and quakes.

More from the world desk